Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome

Abstract

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form

1 . A method of treating complex regional pain syndrome comprising orally administering zoledronic acid to a human being in need thereof, wherein the human being receives about 400 to about 500 mg of zoledronic acid within a period of six months. 
     
     
         2 . The method of  claim 1 , wherein the human being receives zoledronic acid no more often than once daily. 
     
     
         3 . The method of  claim 1 , wherein the human being does not eat food or drink beverage for at least 30 minutes after the zoledronic acid is administered. 
     
     
         4 . The method of  claim 1 , wherein the human being does not eat food or drink beverage for at least 30 minutes before the zoledronic acid is administered. 
     
     
         5 . The method of  claim 1 , wherein the human being does not eat food or drink beverage for at least 60 minutes after the zoledronic acid is administered. 
     
     
         6 . The method of  claim 1 , wherein the human being does not eat food or drink beverage for at least 60 minutes before the zoledronic acid is administered. 
     
     
         7 . The method of  claim 1 , wherein the zoledronic acid is orally administered no more often than once weekly. 
     
     
         8 . The method of  claim 1 , wherein the zoledronic acid is orally administered weekly. 
     
     
         9 . The method of  claim 1 , wherein the zoledronic acid is orally administered 2 to 5 times in a month. 
     
     
         10 . The method of  claim 1 , wherein the zoledronic acid is orally administered once a month, or less frequently. 
     
     
         11 . The method of  claim 1 , wherein zoledronic acid is orally administered within a period of three months. 
     
     
         12 . The method of  claim 1 , wherein zoledronic acid is orally administered within a period of two months. 
     
     
         13 . The method of  claim 1 , wherein the zoledronic acid is orally administered weekly for one to two months. 
     
     
         14 . The method of  claim 1 , wherein at least 300 mg zoledronic acid is administered within the first month of treatment. 
     
     
         15 . The method of  claim 1 , wherein the zoledronic acid is administered in individual doses comprising about 140 mg to about 180 mg of zoledronic acid. 
     
     
         16 . The method of  claim 1 , wherein a total of about 450 mg to about 500 mg of zoledronic acid is administered. 
     
     
         17 . The method of  claim 1 , wherein the zoledronic acid is orally administered in a dosage form containing at least 10% zoledronic acid. 
     
     
         18 . The method of  claim 1 , wherein at least three doses of zoledronic acid are orally administered to the human being. 
     
     
         19 . The method of  claim 1 , wherein three doses of about 150 mg to about 170 mg of zoledronic acid are orally administered within a period of two months. 
     
     
         20 . The method of  claim 1 , wherein two or three doses of about 100 mg to about 150 mg of zoledronic acid are orally administered within a period of two months. 
     
     
         21 . The method of  claim 1 , wherein two doses of about 200 mg to about 250 mg of zoledronic acid are orally administered within a period of two months. 
     
     
         22 . The method of  claim 1 , wherein the human being is suffering from complex regional pain syndrome Type I. 
     
     
         23 . The method of  claim 1 , wherein the human being is suffering from complex regional pain syndrome Type II. 
     
     
         24 . The method of  claim 1 , wherein the human being experiences pain relief for at least 48 hours. 
     
     
         25 . The method of  claim 1 , wherein at least some of the zoledronic acid is in a salt form. 
     
     
         26 . The method of  claim 1 , wherein the dosage form further comprises water. 
     
     
         27 . The method of  claim 1 , wherein the dosage form further comprises magnesium stearate.